New rabies vaccine breakthrough could transform global access

USA – A potential game-changing rabies vaccine developed by researchers at the University of Colorado Boulder could revolutionise access to lifesaving immunisation in low-resource regions, offering hope against a virus that still kills about 60,000 people globally every year.

The new vaccine, described in the Journal of Pharmaceutical Sciences in August 2025, is both temperature-stable and designed to deliver multiple timed-release doses in a single injection. 

Unlike traditional rabies vaccines, which must be kept at cold or even freezing temperatures and require three to five separate doses, the CU Boulder innovation can withstand heat and simplify treatment to a one-time visit.

“We think the implications of this are huge,” said Ted Randolph, a professor in CU Boulder’s Department of Chemical and Biological Engineering and lead author of the study. “We’re really excited about it.”

Breaking barriers to rabies protection

Rabies is rare in developed countries thanks to pet vaccination programs and accessible post-exposure treatment. 

But in rural parts of Africa and Asia, limited healthcare access and lack of cold storage infrastructure mean vaccines often fail to reach those most at risk. A single power outage can ruin supplies, leaving communities vulnerable.

Current rabies vaccines degrade quickly if not refrigerated. “The proteins basically want to make cheese,” Randolph explained. “You have to keep them from making cheese for long enough that you can manufacture the vaccines, get them to pharmacies and hospitals, and get them to patients.”

The CU Boulder team’s approach overcomes this problem by stabilising the vaccine in a unique sugar-based powder that resists heat. Patients would no longer need to travel multiple times for separate doses, a major barrier in regions where clinics are far apart.

The process works by spray-drying solutions of inactivated rabies viruses into microparticles with a hard-candy-like texture. These are then coated with a nanoscopic layer of sapphire using atomic layer deposition, a method pioneered at CU Boulder.

The sapphire coating dissolves gradually in the body, releasing the vaccine at controlled intervals, essentially turning one shot into several timed doses. 

In early animal trials, a single injection of the powder-based vaccine produced stronger immune responses in mice than multiple doses of the traditional liquid vaccine. Remarkably, the immune response held steady even after the vaccines were stored at 104 degrees Fahrenheit for three months.

A path toward human trials

Although human clinical trials are still a few years away, the findings suggest the method could be applied to other vaccines, including those for HPV and HIV. 

Randolph and his colleague, professor emeritus Robert Garcea, have launched a startup called VitriVax to bring the innovation to market.

“It’s been 25 years of lots of talented grad students adding little bits and pieces to the puzzle. It’s the kind of thing that does require long-term dedication, work and funding,” Randolph said.

If successful, the vaccine could remove one of the biggest barriers to rabies prevention in the developing world, cold storage, and drastically cut the number of lives lost to the disease every year.

Sign up HERE to receive our email newsletters with the latest news updates and insights from Africa and the World, and follow us on our WhatsApp channel for updates.